t
| Date | 18 Oct 2022 |
| Time | 09:00:04 |
| Category | Results |
| ID | 2461D |
MGC Pharmaceuticals Ltd.
2022 AGM Notice of Meeting and Annual Report
18 October 2022
ASX, LSE: MXC
MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') a European based bio-pharma company specialising in the production and development of plant inspired medicines, provides the following documents in relation to its 2022 Annual General Meeting of shareholders, scheduled for Thursday 24 November 2022.
The Company advises that its Annual General Meeting will be held in London at the offices of its UK Legal advisors as set out in the Notice of Meeting which can be found at the following URL:
- https://www.asx.com.au/asxpdf/20221018/pdf/45gf34bv50twxj.pdf
A copy of MGC Pharma's Annual Report for the year ended 30 June 2022 can also be found at the URL below:
- https://www.asx.com.au/asxpdf/20221018/pdf/45gf3jq7vpb905.pdf
--Ends--
Authorised for release by the Chairman, for further information please contact:
|
MGC Pharmaceuticals Ltd Roby Zomer CEO & Managing Director +61 8 6382 3390 |
MGC Pharmaceuticals Ltd David Lim Company Secretary +61 8 6382 3390 |
|
UK Financial and Corporate Advisor Hannam & Partners Rupert Fane / Nilesh Patel +44 207 907 8500 |
UK Broker Turner Pope Andy Thacker +44 203 657 0050 |
|
UK PR Advisors Tavistock Charles Vivian / Tim Pearson +44 207 920 3150
|
|
About MGC Pharma
MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based bio-pharma company, focused on developing and supplying accessible and ethically produced plant inspired medicines, combining in-house research with innovative technologies, with the goal of finding or producing treatments to for unmet medical conditions.
The Company's founders and executives are key figures in the global pharmaceuticals industry and the core business strategy is to develop and supply high quality plant inspired medicines for the growing demand in the medical markets in Europe, North America and Australasia.
MGC Pharma has a robust development pipeline targeting two widespread medical conditions and has further products under development.
MGC Pharma has partnered with renowned institutions and academia to optimise the development of targeted plant inspired medicines, to be produced in the Company's EU-GMP Certified manufacturing facilities.
MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.
Follow us through our social media channels:
Twitter: @MGC_Pharma
Facebook: @mgcpharmaceuticals
LinkedIn: MGC Pharmaceuticals Ltd.
Instagram: @mgc_pharma